5-Amino-1MQ Results Timeline: What Studies Measured, and When

The short answer: the human timeline has not been published

5-Amino-1MQ is described in the scientific literature as a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and sits at the intersection of NAD+ handling, methyl-group metabolism and epigenetic regulation, as set out in a 2021 review in Molecular Metabolism (PMID 33453420). No controlled human trial of this compound with serial outcome measurements at defined weeks or months appears in the verified literature summarised here, which means any statement of the form "results appear by week X" would not be traceable to a published human dataset. What does exist is a body of animal and cell-based work in which researchers measured specific biological endpoints after a period of NNMT inhibition, plus observational human tissue studies in which NNMT levels were measured as a marker rather than as a treatment target.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, medication or supplement. Nothing below describes an outcome anyone should expect, and none of the studies cited were designed to forecast personal results.

How to read a "timeline" in preclinical research

In animal work, an endpoint is typically measured once or twice — at the close of a dosing period, or after a standardised injury — rather than tracked continuously the way a human trial might track weight, strength or lab values every few weeks. A rodent study that reports improved tissue function is therefore reporting a state at a measurement point, not a curve describing when a change first became detectable. The 2021 review framed NNMT as a node connecting cellular metabolism to epigenetic regulation, a mechanism category that can shift biochemical readouts long before any visible tissue-level change (PMID 33453420). That distinction — molecular endpoint versus functional endpoint — is the single most useful lens for interpreting the studies below.

Three layers of endpoint

• Molecular and enzymatic: NNMT activity, methylation marks, NAD+-related chemistry. The 2021 review described these as the core of NNMT biology (PMID 33453420).
• Cellular and tissue: stem-cell activation, fibrosis, tissue architecture. A 2019 study in Biochemical Pharmacology reported that a small-molecule NNMT inhibitor activated senescent muscle stem cells in aged skeletal muscle (PMID 30753815).
• Functional: whole-organ or whole-animal performance, such as the improved cardiac function reported in a 2025 Pharmacological Research mouse study of NNMT inhibition (PMID 40484359).

What the preclinical studies measured

Aged skeletal muscle and regenerative capacity (mouse, 2019)

The study published in Biochemical Pharmacology in 2019 examined a small-molecule NNMT inhibitor and reported that it activated senescent muscle stem cells and improved the regenerative capacity of aged skeletal muscle (PMID 30753815). This is animal work, and the endpoints were regenerative and cellular rather than cosmetic or body-composition measures in people. Readers encountering timeline claims about muscle or recovery most often meet a paraphrase of this report, so it is worth noting precisely what the researchers reported: activation of a stem-cell population and improved regeneration in aged muscle, in mice, not a human performance outcome at a named week.

Cardiac function in a heart-failure model (mouse, 2025)

A 2025 report in Pharmacological Research tested NNMT inhibition in a mouse model of heart failure with preserved ejection fraction and reported improvement in both cardiac function and cardiac structure (PMID 40484359). Structural remodelling of the heart is, by its nature, a slower endpoint than a biochemical one — but the study measured the model's state at its defined endpoint, and no human cardiac timeline follows from it. The same paper is sometimes cited loosely as evidence of "cardiovascular results"; what the researchers reported was a model-based improvement in function and structure in mice.

Limb function in experimental peripheral artery disease (2025)

A 2025 study in Physiological Reports reported that NNMT inhibition improved limb function in an experimental model of peripheral artery disease (PMID 41108586). Again the endpoint was functional and the setting experimental. Functional recovery endpoints in vascular models depend heavily on the injury protocol used, which is another reason the measurement point in such a study cannot be mapped onto a calendar for a person.

Human tissue studies: NNMT as a marker, not a treated target

Some of the human-derived data in this field measured NNMT itself rather than the effect of inhibiting it. A 2023 study in the International Journal of General Medicine evaluated nicotinamide N-methyltransferase as a predictive marker of tubular fibrosis in chronic kidney disease (PMID 37576910). That is a biomarker question: it tells readers that NNMT expression carries information about tissue state in a human disease, not that inhibiting the enzyme produced a measured change in patients over any given number of weeks.

Tumour biology: a reminder that NNMT context matters

Several papers examined NNMT inside the tumour microenvironment. A 2024 paper in the Journal for ImmunoTherapy of Cancer reported that NNMT in cancer-associated fibroblasts drove tumour progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (PMID 39067875). A 2026 Oncogene report described disrupting RBP-J-mediated NNMT signalling in the tumour microenvironment as a way of enhancing glioma immunotherapy (PMID 42310095), and a 2026 MedComm paper reported that NNMT epigenetically activated fibronectin 1 through H3K9me3 remodelling in clear cell renal cell carcinoma (PMID 42440812). These are disease-biology studies rather than timeline studies, and they illustrate that NNMT activity is interpreted very differently depending on tissue and context.

Endpoint map: what was measured, in whom

Why animal timepoints do not translate into human weeks

Three structural differences block the translation. First, dosing regimens in rodent studies are designed around the model, not around human pharmacokinetics; the 2025 heart-failure study measured outcomes in a mouse model built to express a specific disease phenotype (PMID 40484359). Second, the biological clocks differ: regeneration in aged mouse muscle, as the 2019 study measured it, proceeds on a murine schedule (PMID 30753815). Third, the endpoints themselves are not endpoints a person can observe — stem-cell senescence status and tissue architecture are assessed on tissue, not in a mirror or on a scale.

There is also a mechanistic reason for caution about speed. Because NNMT sits upstream of methylation-dependent processes, including the H3K9me3 remodelling described in the 2026 clear cell renal cell carcinoma report (PMID 42440812), changes at the enzymatic level and changes at the tissue level need not occur on the same schedule. A measurable biochemical shift does not imply a functional one, and the reverse inference is equally unsupported.

Adverse Events and Tolerability: What Studies Report

The verified literature summarised here reports disease-model efficacy endpoints and tumour biology rather than human safety surveillance, so no published adverse-event rate, onset window or tolerability timeline for 5-Amino-1MQ in people is available to cite. The closest relevant signal is contextual: NNMT activity has been reported to influence disease-relevant processes in multiple directions, including tumour progression and immunotherapy resistance driven by NNMT in cancer-associated fibroblasts in urothelial bladder cancer (PMID 39067875) and signalling in the glioma tumour microenvironment (PMID 42310095). The 2021 review described NNMT as a regulator spanning metabolism and epigenetics, a breadth that researchers flagged as mechanistically significant (PMID 33453420). Absence of reported harms in this citation set is not evidence of safety; it reflects that these papers did not study human tolerability.

Regulatory status in plain terms

5-Amino-1MQ is not an approved drug product. Material described as research-use-only is not supplied for human administration, and compounds appearing only in preclinical publications such as the 2019 aged-muscle study have not passed through the human trial sequence that would generate an approved label or a documented onset-of-effect profile (PMID 30753815).

What would be required for a genuine timeline

1. Phase 1 human pharmacokinetics establishing exposure over time — absent from the literature cited here, which is preclinical or observational (PMID 41108586).
2. Pre-specified human endpoints measured repeatedly, in contrast to single-endpoint model measurements such as the cardiac structure assessment researchers reported in mice (PMID 40484359).
3. Controlled comparison groups, so that change over time can be separated from background variation — a requirement no 5-Amino-1MQ human study in this set fulfils, while human NNMT data remain observational (PMID 37576910).

Until such data are published, the honest answer to "how long does it take" is that the question has not been studied in humans, and the available literature describes mechanism and model-based endpoints instead.

References

• Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle (Biochemical Pharmacology, 2019)
• Nicotinamide N-methyltransferase: At the crossroads between cellular metabolism and epigenetic regulation (Molecular Metabolism, 2021)
• Nicotinamide N-Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD (International Journal of General Medicine, 2023)
• NAD(+) metabolism enzyme NNMT in cancer-associated fibroblasts drives tumor progression and resistance to immunotherapy by modulating macrophages in urothelial bladder cancer (Journal for ImmunoTherapy of Cancer, 2024)
• Nicotinamide-N-methyltransferase inhibition improves cardiac function and structure in a heart failure with preserved ejection fraction mouse model (Pharmacological Research, 2025)
• Nicotinamide N-methyltransferase inhibition improves limb function in experimental peripheral artery disease (Physiological Reports, 2025)
• Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment (Oncogene, 2026)
• Nicotinamide N-Methyltransferase Epigenetically Activates Fibronectin 1 Through H3K9me3 Remodeling in Clear Cell Renal Cell Carcinoma (MedComm, 2026)